Abstract
Proteases have long played a central role in the molecular pathogenesis of Alzheimer ’ s disease (AD), yet proteases that degrade the amyloid β-protein (Aβ) itself were largely ignored until only quite recently. Today, we know that Aβ-degrading proteases are critical regulators of brain Aβ levels in vivo, with evidence accumulating that their dysfunction may play a role in the etiology of AD. This review explores the historical factors that obscured this important aspect of amyloidogenesis, and discusses the many fresh insights it offers into the causes of and potential treatments for AD.
Keywords: Alzheimer's disease, proteases, amyloid, amyloidogenesis, catabolism
Current Alzheimer Research
Title: Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease
Volume: 3 Issue: 5
Author(s): Malcolm A. Leissring
Affiliation:
Keywords: Alzheimer's disease, proteases, amyloid, amyloidogenesis, catabolism
Abstract: Proteases have long played a central role in the molecular pathogenesis of Alzheimer ’ s disease (AD), yet proteases that degrade the amyloid β-protein (Aβ) itself were largely ignored until only quite recently. Today, we know that Aβ-degrading proteases are critical regulators of brain Aβ levels in vivo, with evidence accumulating that their dysfunction may play a role in the etiology of AD. This review explores the historical factors that obscured this important aspect of amyloidogenesis, and discusses the many fresh insights it offers into the causes of and potential treatments for AD.
Export Options
About this article
Cite this article as:
Leissring A. Malcolm, Proteolytic Degradation of the Amyloid β-Protein: The Forgotten Side of Alzheimers Disease, Current Alzheimer Research 2006; 3 (5) . https://dx.doi.org/10.2174/156720506779025206
DOI https://dx.doi.org/10.2174/156720506779025206 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Blood-brain Barrier Dysfunction in Cerebrovascular Diseases
Current Neuropharmacology Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Adipose Derived Stem Cells for Musculoskeletal Regeneration: Recent Patents and Future Perspectives
Recent Patents on Regenerative Medicine Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Roles of Glutamate and Glutamine Transport in Ammonia Neurotoxicity: State of the Art and Question Marks
Endocrine, Metabolic & Immune Disorders - Drug Targets The Antidiabetic PPARγ Ligands: An Update on Compounds in Development
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Regenerative Treatment in Spinal Cord Injury
Current Stem Cell Research & Therapy Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design A Review on Injury Mechanism of Intracerebral Hemorrhage in Vehicle Accidents
Current Pharmaceutical Design Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca<sup>2+</sup> Permeable α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
CNS & Neurological Disorders - Drug Targets Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Pharmacologic Strategies for Suppression of Lipid Peroxidation in Neurodegeneration
Current Neuropharmacology Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Toll-Like Receptor 4 Signaling Pathway as a Potential Targets for Stroke-Induced Inflammation
Current Signal Transduction Therapy Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Structural Design and Physicochemical Foundations of Hydrogels for Biomedical Applications
Current Medicinal Chemistry Pediatric Epilepsy Surgery: Neuropsychological and Psychosocial Outcomes
Current Pediatric Reviews